Literature DB >> 14681327

Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.

Jerzy Lasota1, Agnieszka Dansonka-Mieszkowska, Tomasz Stachura, Regine Schneider-Stock, Markku Kallajoki, Sonja E Steigen, Maarit Sarlomo-Rikala, Carsten Boltze, Radzislaw Kordek, Albert Roessner, Jerzy Stachura, Markku Miettinen.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express KIT and have KIT mutations. Majority of these mutations cluster in the 5' end of the KIT juxtamembrane domain. Little is known about the clinicopathological profile of GIST carrying internal tandem duplications in the 3' end of KIT juxtamembrane domain (ITDs in the 3' KIT-JM). In this study, 500 immunohistochemically KIT-positive GISTs were screened for this type of mutation, and 18 cases were identified (3.6%). The majority of the ITDs consisted of 1 to 18 codon duplications, with Tyr(578), Asp(579), and Leu(576) being the most commonly duplicated codons. There were 14 gastric (78%), 2 small intestinal (11%), and 2 anal (11%) primary tumors diagnosed in 12 females and 6 males with median age of 71 years. The frequency of IDTs in gastric GISTs was 6.5% and was only 0.5% in intestinal GISTs. There was a strong female predominance (79%) among the patients with gastric tumors. Histologically, 16 GISTs were spindle cell, and 2 had epithelioid morphology. The sizes of primary tumors varied from 1 to >20 cm. Based on the combination of tumor size and mitotic activity, six tumors were classified as benign or probably benign, eight as having uncertain malignant potential, and only four as malignant. Follow-up data available in 17 patients confirmed the malignant course of disease in 3 cases. Only one of the tumors classified as potentially malignant metastasized, although the follow-up was limited in some cases. In summary, the great majority of GISTs with ITDs in the 3' KIT-JM were mitotically inactive tumors occurring predominantly in the stomach and that seemed to have a favorable course. This suggests that presence of these IDTs may define a clinicopathologically favorable subset of GISTs. The consequence of these mutations to KIT signaling should be investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14681327     DOI: 10.1097/01.MP.0000097365.72526.3E

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Cristina R Antonescu; Ronald P DeMatteo; Kristen N Ganjoo; Robert G Maki; Peter W T Pisters; Chandrajit P Raut; Richard F Riedel; Scott Schuetze; Hema M Sundar; Jonathan C Trent; Jeffrey D Wayne
Journal:  J Natl Compr Canc Netw       Date:  2010-04       Impact factor: 11.908

2.  A case of gastrointestinal stromal tumor with internal tandem duplication in the 3'-terminal of the KIT juxtamembrane domain.

Authors:  Hideaki Kato; Makoto Nakamura; Etsuro Orito; Ryuzo Ueda; Toyonori Tsuzuki; Masashi Mizokami
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

3.  The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.

Authors:  R Penzel; S Aulmann; M Moock; M Schwarzbach; R J Rieker; G Mechtersheimer
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

4.  Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Authors:  Jerzy Lasota; Bartosz Wasag; Sonja E Steigen; Janusz Limon; Markku Miettinen
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 5.  An update on molecular genetics of gastrointestinal stromal tumours.

Authors:  L Tornillo; L M Terracciano
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

6.  Analysis of mutation of the c-Kit gene and PDGFRA in gastrointestinal stromal tumors.

Authors:  Chun-Wei Xu; Shan Lin; Wu-Long Wang; Wen-Bin Gao; Jin-Yan Lv; Jing-Shan Gao; Li-Ying Zhang; Yang Li; Lin Wang; Yu-Ping Zhang; Yu-Wang Tian
Journal:  Exp Ther Med       Date:  2015-07-02       Impact factor: 2.447

Review 7.  Perspectives on the evolving state of the art management of gastrointestinal stromal tumours.

Authors:  Zoltan Szucs; Robin L Jones
Journal:  Transl Gastroenterol Hepatol       Date:  2018-04-26

8.  [Pathology and molecular biology of gastrointestinal stromal tumors (GIST)].

Authors:  H-U Schildhaus; S Merkelbach-Bruse; R Büttner; E Wardelmann
Journal:  Radiologe       Date:  2009-12       Impact factor: 0.635

9.  GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Zengfeng Wang; Shingo Inaguma; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2017-05       Impact factor: 6.394

Review 10.  Extragastrointestinal stromal tumors of the omentum: review apropos of a case with a novel gain-of-function KIT mutation.

Authors:  Georgia Dedemadi; George Georgoulis; Dimitrios Kontopanos; Evangelos Anagnostou; George Morphopoulos; Jean-François Emile; Constantinos Christopoulos
Journal:  J Gastrointest Cancer       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.